Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04680338
Other study ID # NL64860.042.18
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date May 27, 2019
Est. completion date December 2024

Study information

Verified date April 2021
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Early-Synergy investigates a diagnostic imaging approach in asymptomatic individuals from the general population for early detection of silent myocardial ischemia and cardiac dysfunction. The diagnostic imaging approach consists of cardiac computed tomography for coronary artery calcium scoring (CT-CAC) and cardiac magnetic resonance (CMR) stress perfusion imaging. Early-Synergy investigates the effect of early detection of silent myocardial ischemia and cardiac dysfunction by CMR in asymptomatic individuals with increased CAC. In addition, the diagnostic yield of CMR for early detection of silent myocardial ischemia and cardiac dysfunction is investigated. Asymptomatic individuals at increased risk (CAC ≥ 300) are therefore randomized 1:1 to either CMR stress perfusion imaging or a control group.


Description:

Early-Synergy is a prospective multi-center study performed in the Netherlands. Potential candidates for participation in Early-Synergy have had CT-CAC scanning as part of participation in two ongoing population-based studies (ROBINSCA and ImaLife) and had CAC ≥300. Participants are randomized in a 1:1 fashion to (1.) CMR stress perfusion imaging with feedback of clinically actionable findings or (2.) control group. In the CMR group, feedback on CMR stress perfusion imaging is provided to the participant and general practitioner only in case of CMR findings that require further management based on current clinical guidelines. Participants in the control group will not receive stress CMR perfusion imaging but will be followed in time to evaluate the clinical presentation of the natural course of coronary atherosclerosis. Follow-up will be performed up to 5 years in both groups by sending questionnaires and collecting medical information from health care providers and registries. Additionally, blood is drawn from participants in the CMR group during the hospital visit for CMR scanning and is stored to allow evaluation of cardiac blood markers as predictors of CMR findings.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 1400
Est. completion date December 2024
Est. primary completion date December 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years and older
Eligibility Inclusion Criteria: - Participation in ROBINSCA or ImaLife study - CT-CAC =300 Exclusion Criteria: - History of ischemic heart disease or other cardiac disease (myocardial infarction, sudden cardiac arrest, heart failure, cardiomyopathy, congenital cardiac disease, percutaneous coronary intervention, coronary artery bypass grafting surgery, valvular surgery, other major cardiac surgery (e.g. cardiac transplantation) and/or previous invasive coronary angiography or catheter ablation) - Contra-indication for stress CMR perfusion imaging (claustrophobia, CMR incompatible device (e.g., Implantable Cardioverter Defibrillator/pacemaker), contrast agent or vasodilator intolerance, contra-indications for adenosine or regadenoson (e.g. 2nd/3rd degree atrioventricular block, severe hypotension) and/or weight > 125 kg) - Severe comorbidity and/or a life expectancy of less than 1 year - Unable to provide written informed consent - Pregnancy

Study Design


Intervention

Diagnostic Test:
CMR stress perfusion imaging
CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
Pim van der Harst

Country where clinical trial is conducted

Netherlands, 

References & Publications (2)

Vonder M, van der Aalst CM, Vliegenthart R, van Ooijen PMA, Kuijpers D, Gratama JW, de Koning HJ, Oudkerk M. Coronary Artery Calcium Imaging in the ROBINSCA Trial: Rationale, Design, and Technical Background. Acad Radiol. 2018 Jan;25(1):118-128. doi: 10.1016/j.acra.2017.07.010. Epub 2017 Aug 23. Review. — View Citation

Xia C, Rook M, Pelgrim GJ, Sidorenkov G, Wisselink HJ, van Bolhuis JN, van Ooijen PMA, Guo J, Oudkerk M, Groen H, van den Berge M, van der Harst P, Dijkstra H, Vonder M, Heuvelmans MA, Dorrius MD, De Deyn PP, de Bock GH, Dotinga A, Vliegenthart R. Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) Study. Eur J Epidemiol. 2020 Jan;35(1):75-86. doi: 10.1007/s10654-019-00519-0. Epub 2019 Apr 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Cost-effectiveness Cost-effectiveness of CMR stress perfusion imaging compared to control group 1 year
Other Cost-effectiveness Cost-effectiveness of CMR stress perfusion imaging compared to control group 2.5 years
Other Cost-effectiveness Cost-effectiveness of CMR stress perfusion imaging compared to control group 5 years
Primary Rate of major adverse cardiac events Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest 1 year
Primary Rate of major adverse cardiac events Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest 2.5 years
Primary Rate of major adverse cardiac events Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest 5 years
Primary Diagnostic yield of CMR stress perfusion imaging Prevalence and extent of silent myocardial ischemia and cardiac dysfunction Baseline
Secondary Rate of individual components of primary outcome 1 Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest 1 year
Secondary Rate of individual components of primary outcome 1 Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest 2.5 years
Secondary Rate of individual components of primary outcome 1 Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest 5 years
Secondary All-cause mortality rate Death from any disease 1 year
Secondary All-cause mortality rate Death from any disease 2.5 years
Secondary All-cause mortality rate Death from any disease 5 years
Secondary Rate of invasive cardiovascular procedures percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) surgery, invasive coronary angiography (ICA) and other invasive cardiovascular procedures 1 year
Secondary Rate of invasive cardiovascular procedures percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) surgery, invasive coronary angiography (ICA) and other invasive cardiovascular procedures 2.5 years
Secondary Rate of invasive cardiovascular procedures percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) surgery, invasive coronary angiography (ICA) and other invasive cardiovascular procedures 5 years
Secondary Rate of hospitalization for cardiovascular disease Hospitalization for cardiovascular disease (e.g. stroke, peripheral vascular disease) 1, 2.5, 5 years
Secondary Rate of hospitalization for cardiovascular disease Hospitalization for cardiovascular disease (e.g. stroke, peripheral vascular disease) 1 year
Secondary Rate of hospitalization for cardiovascular disease Hospitalization for cardiovascular disease (e.g. stroke, peripheral vascular disease) 2.5 years
Secondary Rate of non-invasive cardiac imaging procedures Rate of non-invasive cardiac imaging procedures (e.g., myocardial stress perfusion imaing, echocardiography) 5 years
Secondary Rate of medical therapy initiation Initiation of preventive or cardio-active medication (e.g., ACE-inhibiters, statins, calcium antagonists, beta-blockers etc.) 1 year
Secondary Rate of medical therapy initiation Initiation of preventive or cardio-active medication (e.g., ACE-inhibiters, statins, calcium antagonists, beta-blockers etc.) 2.5 years
Secondary Rate of medical therapy initiation Initiation of preventive or cardio-active medication (e.g., ACE-inhibiters, statins, calcium antagonists, beta-blockers etc.) 5 years
Secondary Quality of Life as reflected by EQ-5D-5S score Quality of life as assessed by EQ-5D-5S questionnaire 1 year
Secondary Quality of Life as reflected by EQ-5D-5S score Quality of life as assessed by EQ-5D-5S questionnaire 2.5 years
Secondary Quality of Life as reflected by EQ-5D-5S score Quality of life as assessed by EQ-5D-5S questionnaire 5 years
Secondary Quality of Life as reflected by HeartQoL score Quality of life as assessed by HeartQoL questionnaire 1 year
Secondary Quality of Life as reflected by HeartQoL score Quality of life as assessed by HeartQoL questionnaire 2.5 years
Secondary Quality of Life as reflected by HeartQoL score Quality of life as assessed by HeartQoL questionnaire 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)